A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy.

Trial Profile

A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Amlodipine/valsartan; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 May 2011 This trial is completed in Latvia and Lithuania.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top